NASDAQ:PRTA - Prothena Stock Price, Forecast & News

Prothena trades on the NASDAQ under the ticker symbol "PRTA."

Prothena Co. PLC (NASDAQ:PRTA) posted its quarterly earnings results on Tuesday, November, 5th. The biotechnology company reported ($0.49) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.54) by $0.05. The biotechnology company earned $0.21 million during the quarter, compared to the consensus estimate of $0.15 million. Prothena had a negative return on equity of 26.02% and a negative net margin of 10,450.00%. View Prothena's Earnings History.

Prothena is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for Prothena.

3 equities research analysts have issued 1-year price objectives for Prothena's shares. Their forecasts range from $9.00 to $14.00. On average, they expect Prothena's stock price to reach $12.26 in the next year. This suggests that the stock has a possible downside of 6.2%. View Analyst Price Targets for Prothena.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Prothena.

Media stories about PRTA stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Prothena earned a media sentiment score of 1.2 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Prothena.

Some companies that are related to Prothena include Cambrex (CBM), Ironwood Pharmaceuticals (IRWD), Prestige Consumer Healthcare (PBH), Pacira Biosciences (PCRX), Aimmune Therapeutics (AIMT), Ligand Pharmaceuticals (LGND), Turning Point Therapeutics (TPTX), Dicerna Pharmaceuticals (DRNA), Madrigal Pharmaceuticals (MDGL), ChemoCentryx (CCXI), Gossamer Bio (GOSS), Epizyme (EPZM), Akcea Therapeutics (AKCA), Zymeworks (ZYME) and Axsome Therapeutics (AXSM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include Canopy Growth (CGC), Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BIOLINERX LTD/S (BLRX), Perrigo (PRGO), Celgene (CELG) and Synergy Pharmaceuticals (SGYP).

Prothena's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Orbimed Advisors LLC (7.57%), Great Point Partners LLC (5.18%), Millennium Management LLC (3.08%), State Street Corp (3.00%), Tang Capital Management LLC (1.06%) and Man Group plc (0.24%). View Institutional Ownership Trends for Prothena.

PRTA stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Squarepoint Ops LLC, Man Group plc, Orbimed Advisors LLC, Russell Investments Group Ltd. and Rhumbline Advisers. View Insider Buying and Selling for Prothena.

PRTA stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Great Point Partners LLC, Tang Capital Management LLC, Endurant Capital Management LP, Campbell & CO Investment Adviser LLC, California Public Employees Retirement System, Meeder Asset Management Inc. and Focused Wealth Management Inc. View Insider Buying and Selling for Prothena.

Shares of PRTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PRTA stock can currently be purchased for approximately $13.06.

Prothena has a market capitalization of $521.09 million and generates $950,000.00 in revenue each year. The biotechnology company earns $-155,650,000.00 in net income (profit) each year or ($3.61) on an earnings per share basis. Prothena employs 59 workers across the globe.View Additional Information About Prothena.

The official website for Prothena is http://www.prothena.com/.

Prothena's mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN L2, D02 T804. The biotechnology company can be reached via phone at 011-353-1236-2500 or via email at [email protected]